This pre-doctoral Pharmacological Sciences Training Program (PSTP) is a cross-disciplinary program that represents a merger of research training opportunities in the Schools of Medicine (Pharmacology) and Pharmacy (Medicinal Chemistry and Pharmaceutics) at the University of Washington. The rationale for this program is that it is essential for providing in-depth training in several inter-related disciplines that are central to current and future research related to the discovery, validation and development of new drug targets and new chemical entities that will improve global health. This focus distinguishes training provided by the PSTP from other pre-doctoral training grants available at UW. The primary objective of the PSTP is to develop scientists, equipped with the necessary background in the biological and chemical sciences and training in the application of modern tools of research and instrumental techniques, to undertake and direct fundamental research related to drug action, metabolism and pharmacokinetics. Trainees follow tracks that emphasize training in four broadly defined areas: (I) cellular and molecular pharmacology, (II) structure and drug/vaccine design, (III) drug metabolism, (IV) pharmacokinetics, drug transport and delivery, which exist in the departments of Pharmacology, Medicinal Chemistry and Pharmaceutics. Didactic components involve individualized, highly multidisciplinary programs of coursework and seminars that are centered on the biological and chemical sciences. The program brings together some 40 well-funded faculty members whose research emphasizes training in mechanisms and regulation of cell signaling, neuropharmacology, structural analysis of pharmacologically relevant protein-ligand interactions, mechanistic and bio- analytical aspects of drug metabolism and toxicology, pharmacogenetics, pharmacokinetics/dynamics and drug transporter function and regulation. Under-represented and disadvantaged students, who are actively recruited through a number of faculty activities, currently represent ~10% of the training grant eligible pool of some 70 students. In this revised, competitive renewal of the Pharmacological Sciences National Research Service Award program, support is requested for 16 pre-doctoral trainees per year. The selection of trainees will be on a competitive basis from the pool of students in years 1-3, who are committed to research in one of the aforementioned areas.

Public Health Relevance

The training that is provided relates to how drugs used to treat human diseases and other disorders act on the body (pharmacology), and how the body acts on drugs (metabolism and pharmacokinetics). These fundamental areas of knowledge are critical to optimizing the use of drugs already on the market as well as ongoing national and international efforts to discover and develop new therapeutic agents.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Institutional National Research Service Award (T32)
Project #
5T32GM007750-39
Application #
9307864
Study Section
NIGMS Initial Review Group (TWD)
Program Officer
Koduri, Sailaja
Project Start
1979-07-01
Project End
2019-06-30
Budget Start
2017-07-01
Budget End
2018-06-30
Support Year
39
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of Washington
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Gao, Yu; Kraft, John C; Yu, Danni et al. (2018) Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy. Eur J Pharm Biopharm :
Wong, Timothy; Wang, Zhican; Chapron, Brian D et al. (2018) Polymorphic Human Sulfotransferase 2A1 Mediates the Formation of 25-Hydroxyvitamin D3-3-O-Sulfate, a Major Circulating Vitamin D Metabolite in Humans. Drug Metab Dispos 46:367-379
Abraham, Antony D; Fontaine, Harrison M; Song, Allisa J et al. (2018) ?-Opioid Receptor Activation in Dopamine Neurons Disrupts Behavioral Inhibition. Neuropsychopharmacology 43:362-372
Evangelista, Eric A; Lemaitre, Rozenn N; Sotoodehnia, Nona et al. (2018) CYP2J2 Expression in Adult Ventricular Myocytes Protects Against Reactive Oxygen Species Toxicity. Drug Metab Dispos 46:380-386
Henderson, Lindsay M; Claw, Katrina G; Woodahl, Erica L et al. (2018) P450 Pharmacogenetics in Indigenous North American Populations. J Pers Med 8:
Kraft, John C; Treuting, Piper M; Ho, Rodney J Y (2018) Indocyanine green nanoparticles undergo selective lymphatic uptake, distribution and retention and enable detailed mapping of lymph vessels, nodes and abnormalities. J Drug Target 26:494-504
Abraham, Antony D; Schattauer, Selena S; Reichard, Kathryn L et al. (2018) Estrogen Regulation of GRK2 Inactivates Kappa Opioid Receptor Signaling Mediating Analgesia, But Not Aversion. J Neurosci 38:8031-8043
Kraft, John C; McConnachie, Lisa A; Koehn, Josefin et al. (2018) Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation. J Control Release 275:229-241
Goulet, Dennis R; Orcutt, Steven J; Zwolak, Adam et al. (2018) Kinetic mechanism of controlled Fab-arm exchange for the formation of bispecific immunoglobulin G1 antibodies. J Biol Chem 293:651-661
Rubinstein, M; Patowary, A; Stanaway, I B et al. (2018) Association of rare missense variants in the second intracellular loop of NaV1.7 sodium channels with familial autism. Mol Psychiatry 23:231-239

Showing the most recent 10 out of 149 publications